Bioactivity:

Ralimetinib Mesylate is the dimesylate salt form of LY2228820, a tri-substituted imidazole derivative and orally available, p38 mitogen-activated protein kinase (MAPK) inhibitor with potential anti-inflammatory and antineoplastic activities.

CAS nr:

862507-23-1

Purity:

98%

Molecular Weight:

612,74

SMILES:

CC(C)(C)Cn1c2c(ccc(n2)c2c(nc([nH]2)C(C)(C)C)c2ccc(cc2)F)nc1N.CS(=O)(=O)O.CS(=O)(=O)O

Formula:

C24H29FN6�2CH4O3S

Pathway:

Autophagy,Apoptosis,MAPK

Target:

Autophagy,Apoptosis,p38 MAPK